/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Masashi Ando

Aichi Cancer Center(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

309

Papers

4.8K

Citations

36

h-index

105

i10-index

Masashi Ando is an academic researcher from Aichi Cancer Center. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Cancer Treatment and Pharmacology & Colorectal Cancer Treatments and Studies. The author has an h-index of 36, co-authored 263 publications.

ORCID: 0000-0002-9537-8879

Research Topics

Gastric Cancer Management and Outcomes Cancer Treatment and Pharmacology Colorectal Cancer Treatments and Studies Breast Cancer Treatment Studies HER2/EGFR in Cancer Research

Papers by this author

works

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

2011 · Breast Cancer Research and Treatment · 303 citations

https://doi.org/10.1007/s10549-011-1554-7

Makiko Ono Hitoshi Tsuda Chikako Shimizu Sohei Yamamoto

FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer

2010 · Annals of Oncology · 181 citations

https://doi.org/10.1093/annonc/mdq585

Kenji Tamura Chikako Shimizu Takashi Hojo Sadako Akashi‐Tanaka

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1999 · British Journal of Cancer · 113 citations

https://doi.org/10.1038/sj.bjc.6690343

Yutaka Tokuda Toru Watanabe Yasushi Omuro Masashi Ando

Efficacy of everolimus, a novel m<scp>TOR</scp> inhibitor, against basal‐like triple‐negative breast cancer cells

2012 · Cancer Science · 95 citations

https://doi.org/10.1111/j.1349-7006.2012.02359.x

Mayu Yunokawa Fumiaki Koizumi Yuka Kitamura Yasufumi Katanasaka

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

2009 · Breast Cancer Research and Treatment · 89 citations

https://doi.org/10.1007/s10549-009-0498-7

Kenichi Inoue Kazuhiko Nakagami Mitsuhiro Mizutani Yasuo Hozumi

Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression

2014 · Breast Cancer Research and Treatment · 75 citations

https://doi.org/10.1007/s10549-014-2947-1

Masashi Ando Hideko Yamauchi Kenjiro Aogi Satoru Shimizu

Research topics

topics

Gastric Cancer Management and Outcomes

Cancer Treatment and Pharmacology

Colorectal Cancer Treatments and Studies

Breast Cancer Treatment Studies

HER2/EGFR in Cancer Research

Chat about Author

Papers

Chat

Click to start Chat